Syncona (LON:SYNC) Sets New 12-Month High – What’s Next?

Syncona (LON:SYNC)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as GBX 117 and last traded at GBX 115.41, with a volume of 10509 shares trading hands. The stock had previously closed at GBX 117.

Wall Street Analyst Weigh In

Separately, Peel Hunt reissued a “buy” rating and issued a GBX 189 price target on shares of Syncona in a research note on Tuesday, August 4th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, Syncona presently has a consensus rating of “Buy” and a consensus target price of GBX 189.

Syncona Trading Down 1.4%

The firm’s 50-day moving average is GBX 107.19 and its two-hundred day moving average is GBX 98.84. The stock has a market cap of £701.93 million, a price-to-earnings ratio of -79.59 and a beta of 0.36.

Insider Buying and Selling

In other news, insider John Roche acquired 16,063 shares of the business’s stock in a transaction on Friday, June 19th. The stock was bought at an average cost of GBX 100 per share, for a total transaction of £16,063. Company insiders own 0.75% of the company’s stock.

Syncona Company Profile

Syncona’s purpose is to invest to extend and enhance human life. We do this by creating, building and scaling companies to deliver transformational treatments to patients in areas of high unmet need. We aim to build and maintain a diversified portfolio of 20-25 globally leading life science businesses, across development stage, modality and therapeutic area, for the benefit of all our stakeholders. We focus on developing treatments that deliver patient impact by working in close partnership with world-class academic founders and experienced management teams.